HTA challenges for appraising rare disease interventions viewed through the lens of an institutional multidimensional value framework
Expert Review of Pharmacoeconomics & Outcomes Research · 07.02.2023 · 23 (2) · 143-152
DOI: 10.1080/14737167.2023.2161513 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 26.12.2022. Verfasst von Monika Wagner und 7 weiteren Autor:innen. Beteiligte Einrichtung: Bureau - Méthodologies et éthique, Institut national d'excellence en santé et en services sociaux (INESSS), 2021 Avenue Union, bureau 1200; Montréal …. Hauptthemen laut MEDLINE: Rare Diseases, Technology Assessment, Biomedical. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: funded.
Abstract (Originalsprache)
INTRODUCTION: Evaluating rare disease interventions poses challenges for HTA agencies, including uncertainties and ethical issues and tensions. INESSS has recently adopted a Statement of Principles and Ethical Foundations which proposes a multidimensional approach to value appraisal as well as five principles to frame the evaluation process. AREAS COVERED: Our aim was to identify and analyze HTA challenges for appraising interventions for rare diseases, using the Statement's approach to value appraisal as an analytical framework, and outline how the Statement's principles can help address these challenges. Challenges, covering a diversity of aspects, were identified by leveraging institutional experience in diverse domains of expertise and consolidated through narrative literature review. Challenges were categorized by value dimension (clinical, populational, economic, organizational, and sociocultural), which allowed to pinpoint how each challenge affects the ability to appraise the value of an intervention. Key ethical tensions across dimensions were also identified. Specific approaches to addressing these challenges - related to knowledge mobilization and integration, deliberation, and recommendation-making - were outlined on the basis of the principles promulgated in the Statement. EXPERT OPINION: A multidimensional approach can be fruitful for analyzing challenges for appraising the value of rare disease interventions and help guide approaches to tackle them.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Bureau - Méthodologies et éthique, Institut national d'excellence en santé et en services sociaux (INESSS), 2021 Avenue Union, bureau 1200; Montréal H3A 2S9, Quebec, Canada.
- School of Public Health, Department of Management, Evaluation and Health Policy, Université de Montréal; 7101, avenue du Parc, 3e étage H3N 1X9 Montréal, Quebec, Canada.
- School of Public Health, Department of Social and Preventive Medicine, Université de Montréal, 7101avenue du Parc, 3e étage H3N 1X9 Montréal, Quebec, Canada.
- Institut national d'excellence en santé et en services sociaux (INESSS), 2021 Avenue Union, bureau 1200; Montréal H3A 2S9, Québec, Canada.
Förderung
- funded
Zitieren
APA
Wagner, M., Goetghebeur, M. M., Ganache, I., Demers-Payette, O., Auclair, Y., Olivier, C., Arbour, S., & de Guise, M. (2023). HTA challenges for appraising rare disease interventions viewed through the lens of an institutional multidimensional value framework. Expert Review of Pharmacoeconomics & Outcomes Research, 23(2), 143-152. https://doi.org/10.1080/14737167.2023.2161513
Vancouver
Wagner M, Goetghebeur MM, Ganache I, Demers-Payette O, Auclair Y, Olivier C, et al. HTA challenges for appraising rare disease interventions viewed through the lens of an institutional multidimensional value framework. Expert Review of Pharmacoeconomics & Outcomes Research. 2023;23(2):143-152. doi:10.1080/14737167.2023.2161513
BibTeX
@article{Wagner2023,
author = {Wagner, Monika and Goetghebeur, Mireille M and Ganache, Isabelle and Demers-Payette, Olivier and Auclair, Yannick and Olivier, Catherine and Arbour, Sylvie and de Guise, Michèle},
title = {HTA challenges for appraising rare disease interventions viewed through the lens of an institutional multidimensional value framework},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2023},
volume = {23},
number = {2},
pages = {143--152},
doi = {10.1080/14737167.2023.2161513}
}
EUVIMED